One-year results from the CLASP IID trial and registry showed outstanding results in patients with significant symptomatic degenerative mitral regurgitation (DMR) for Pascal, Edwards Lifesciences Corp ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
Edwards Lifesciences Corporation EW recently gained CE Mark for its PASCAL Precision transcatheter valve repair system used to treat mitral and tricuspid regurgitation. The PASCAL Precision system is ...
Edwards’ Pascal and Abbott’s MitraClip TEER devices are cleared in the U.S. to repair the mitral valve in patients with mitral regurgitation. The condition occurs when the valve does not shut properly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results